Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹104Cr
Rev Gr TTM
Revenue Growth TTM
7.60%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

DEEPAKCHEM
VS
| Quarter | Mar 2024 | Mar 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | | | 78.8 | 47.0 | -20.4 |
| 18 | 24 | 31 | 32 | 25 |
Operating Profit Operating ProfitCr |
| 19.0 | 13.7 | 20.0 | 21.5 | 19.6 |
Other Income Other IncomeCr | 0 | 1 | 1 | 2 | 1 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 1 | 1 | 1 |
| 5 | 5 | 8 | 10 | 7 |
| 1 | 1 | 2 | 2 | 1 |
|
Growth YoY PAT Growth YoY% | | | 81.3 | 140.2 | -23.2 |
| 14.3 | 10.4 | 14.5 | 16.9 | 14.0 |
| 0.0 | 26.3 | 5.2 | 63.3 | 4.0 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | -14.3 | 6.0 | 59.2 | -8.6 |
| 48 | 39 | 41 | 62 | 57 |
Operating Profit Operating ProfitCr |
| 11.0 | 16.8 | 16.1 | 21.1 | 20.6 |
Other Income Other IncomeCr | 0 | 1 | 1 | 3 | 3 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 1 | 1 | 1 | 2 | 2 |
| 6 | 8 | 8 | 17 | 17 |
| 1 | 2 | 2 | 4 | 4 |
|
| | 44.6 | -2.4 | 109.4 | -10.5 |
| 7.8 | 13.2 | 12.2 | 16.0 | 15.7 |
| 5.3 | 122.6 | 55.0 | 11.5 | 67.3 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Equity Capital Equity CapitalCr | 1 | 1 | 11 | 11 |
| 9 | 15 | 31 | 44 |
Current Liabilities Current LiabilitiesCr | 7 | 8 | 9 | 14 |
Non Current Liabilities Non Current LiabilitiesCr | 0 | 0 | 0 | 1 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 14 | 19 | 43 | 47 |
Non Current Assets Non Current AssetsCr | 3 | 5 | 8 | 24 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 1 | 3 | 2 | -3 |
Investing Cash Flow Investing Cash FlowCr | -1 | -2 | -4 | -16 |
Financing Cash Flow Financing Cash FlowCr | 0 | -1 | 20 | -1 |
|
Free Cash Flow Free Cash FlowCr | 0 | 1 | -2 | -12 |
| 19.4 | 56.8 | 30.2 | -27.9 |
CFO To EBITDA CFO To EBITDA% | 13.8 | 44.8 | 22.8 | -21.1 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 72 | 119 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 12.0 | 9.5 |
Price To Sales Price To Sales | 0.0 | 0.0 | 1.5 | 1.5 |
Price To Book Price To Book | 0.0 | 0.0 | 1.7 | 2.1 |
| 0.3 | 0.1 | 6.8 | 6.9 |
Profitability Ratios Profitability Ratios |
| 30.9 | 37.4 | 40.7 | 41.1 |
| 11.0 | 16.8 | 16.1 | 21.1 |
| 7.8 | 13.2 | 12.2 | 16.0 |
| 50.4 | 48.3 | 19.0 | 30.0 |
| 45.1 | 39.0 | 14.2 | 22.7 |
| 24.7 | 25.7 | 11.7 | 17.8 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
Deepak Chemtex Limited (DCL) is a specialized Indian manufacturer of high-purity synthetic organic colorants, chemical intermediates, and specialty dyes. Established in **1997** and headquartered with manufacturing operations in **Lote, Maharashtra**, the company has transitioned from a niche producer into a high-growth specialty chemicals player. Following its successful **IPO in December 2023**, which raised **₹23.04 Crores**, the company is aggressively expanding its global footprint and vertical integration into consumer-facing markets.
---
### **Specialized Product Portfolio & Market Applications**
Deepak Chemtex has doubled its commercialized product basket from **50 products in FY21** to approximately **100 products by FY23**. The portfolio is engineered to meet stringent global safety standards, including **EN 71 (European Standard)** and **FD&C/D&C** specifications.
* **FD&C and D&C Colors:** High-purity colorants for the food, drug, and cosmetic industries. Key products include **Acid Blue 9 (FD&C Blue No. 1)**, **Acid Violet 43 (Ext. D&C Violet No. 2)**, and **Acid Red 33**. These are available in both **solid/powder** and **liquid** formulations for beverages, confectionery, and premium cosmetics.
* **Specialized & Inkjet Dyes:** Salt-free dyes specifically developed for the **inkjet industry**, alongside pond dyes for aquatic aesthetics and floral dyes.
* **Agrochemical Colorants:** Specialized indicators and colorants for seed treatment, crop protection, and fertilizers.
* **Industrial Colorants:** Applications in car wash products, portable sanitation, detergents, fuel, lubricants, and smoke signaling.
* **Inorganic Chemicals:** Trading and manufacturing of **Sulphuric Acid**, **Zinc Sulphate**, and **Hydrochloric Acid**.
---
### **Manufacturing Infrastructure & Technical Capabilities**
The company’s primary manufacturing hub is located in the **Lote MIDC (Ratnagiri District, Maharashtra)**. The facility is equipped with advanced glass-lined reactors, high-pressure reaction vessels, and purification systems.
* **Core Chemical Processes:** Expertise in Sulphonation, Condensation, Bromination, Oxidation, Reduction, and High-pressure reactions.
* **Capacity Expansion:** The company recently acquired the **B-91 Lote MIDC facility**, which is expected to increase dyestuff capacity by **1,500 MTPA**.
* **New Product Development:** The **DCPL Speciality Unit No. 3** is awaiting "Consent to Operate" (expected **Aug/Sep 2025**), which will introduce **5 substantial new products** to the portfolio.
* **Sustainability & Cost Control:** DCL has operationalized a **solar power project** across its facilities, targeted to reduce electricity expenditures by up to **80%**, significantly boosting operating margins.
---
### **Financial Performance & Capital Structure**
Deepak Chemtex has maintained a growth trajectory exceeding **30%** in the most recent fiscal year, supported by three consecutive years of profitability.
**Standalone Financial Highlights:**
| Metric (Standalone) | FY 2022-23 | FY 2023-24 | FY 2024-25 |
| :--- | :--- | :--- | :--- |
| **Total Revenue** | **₹47.84 Cr** | **₹51.59 Cr** | **₹70.50 Cr** |
| **Profit Before Tax (PBT)** | **₹8.20 Cr** | **₹8.85 Cr** | **₹13.77 Cr** |
| **Net Profit (PAT)** | **₹6.15 Cr** | **₹6.63 Cr** | **₹10.07 Cr** |
**Equity Evolution:**
In 2023, the company restructured its capital to enhance liquidity:
* **Stock Split:** Sub-divided share face value from **₹100** to **₹10** (June 2023).
* **Bonus Issue:** Allotted shares in a **15:1 ratio** (August 2023).
* **Paid-up Capital:** Currently stands at **₹10.86 Crores** comprising **1,08,64,000** equity shares.
---
### **Global Footprint & Subsidiary Strategy**
The company has successfully diversified its revenue away from over-dependence on a few products, with the top 10 products' contribution dropping from **90.97% in FY21** to **75.92% in H1 FY24**.
* **International Reach:** Active exports to **China, France, Mexico, Japan, Australia, the UK, and the USA**.
* **Atlas Tints Inc. (USA):** A wholly-owned foreign subsidiary incorporated in **January 2025** to sell directly to end-consumers in the North American market. It is already reporting sales and profits.
* **DCPL Speciality Chemicals Pvt Ltd:** Classified as a **Material Subsidiary** focusing on high-margin specialty intermediates.
* **South West Corporation:** A wholly-owned subsidiary contributing to the consolidated revenue, which reached **₹50.54 crore** in FY 2023-24.
---
### **Strategic Growth Priorities**
1. **Niche Market Dominance:** Launching a **"Super Specialty" portfolio** of **4 new products** targeting global markets with limited competition.
2. **Vertical Integration:** Moving from being a pure B2B supplier to capturing higher margins through direct-to-consumer (D2C) initiatives via international subsidiaries.
3. **Geographic De-risking:** Actively securing substantial new orders from **China** and other non-US markets to mitigate potential **USA tariff threats**.
4. **Managerial Strengthening:** Appointed **Mr. Ashok Ramchandra Patil** as Executive Director in **April 2024** to align corporate governance and management trends with private sector benchmarks.
5. **Capital Allocation:** Prioritizing **internal accruals** over dividends in the short term to fund aggressive capacity expansions.
---
### **Risk Assessment & Mitigation**
Management actively monitors several operational and regulatory risks:
* **Regulatory Compliance:** The company has addressed past administrative lapses, including delayed **SEBI Regulation 30** intimations and **RBI ODI** compliance regarding foreign subsidiaries. Corrective filings with the **ROC** and **BSE Limited** have been completed.
* **Competitive Pressure:** DCL competes with larger diversified players. Mitigation strategies include continuous **cost reduction** in production and distribution and a focus on **high-purity specialty grades** that larger players may overlook.
* **Governance Enhancements:** Following a secretarial audit identifying the absence of a formal system for pre-meeting clarifications, the board is implementing more robust internal processes.
* **Market Volatility:** By focusing on **Non-USA products** and "super specialty" chemicals, the company aims to insulate its top line from geopolitical trade shifts.